The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
As of 1 July 2024, you may notice a temporary increase in the numbers of X profiles with Unknown location. Click here to learn more.
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
Title |
Clinical Trials of the BTK Inhibitors Ibrutinib and Acalabrutinib in Human Diseases Beyond B Cell Malignancies
|
---|---|
Published in |
Frontiers in oncology, October 2021
|
DOI | 10.3389/fonc.2021.737943 |
Pubmed ID | |
Authors |
Sining Zhu, Jaeyong Jung, Eton Victor, Johann Arceo, Samantha Gokhale, Ping Xie |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 1 | 100% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 38 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 38 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Master | 7 | 18% |
Researcher | 5 | 13% |
Student > Postgraduate | 3 | 8% |
Student > Ph. D. Student | 3 | 8% |
Other | 2 | 5% |
Other | 7 | 18% |
Unknown | 11 | 29% |
Readers by discipline | Count | As % |
---|---|---|
Biochemistry, Genetics and Molecular Biology | 6 | 16% |
Medicine and Dentistry | 5 | 13% |
Agricultural and Biological Sciences | 4 | 11% |
Pharmacology, Toxicology and Pharmaceutical Science | 3 | 8% |
Chemical Engineering | 2 | 5% |
Other | 7 | 18% |
Unknown | 11 | 29% |
Attention Score in Context
This research output has an Altmetric Attention Score of 4. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 22 June 2022.
All research outputs
#7,966,302
of 25,392,582 outputs
Outputs from Frontiers in oncology
#2,906
of 22,436 outputs
Outputs of similar age
#152,975
of 442,599 outputs
Outputs of similar age from Frontiers in oncology
#147
of 1,488 outputs
Altmetric has tracked 25,392,582 research outputs across all sources so far. This one has received more attention than most of these and is in the 67th percentile.
So far Altmetric has tracked 22,436 research outputs from this source. They receive a mean Attention Score of 3.0. This one has done well, scoring higher than 86% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 442,599 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 64% of its contemporaries.
We're also able to compare this research output to 1,488 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 89% of its contemporaries.